Financial News

MGC Pharmaceuticals "totally understands" CimetrA after MoA study

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

--News Direct--

MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) chief medical officer Nadya Lisovoder speaks to Proactive's Thomas Warner after announcing the completion of an in-vitro pre-clinical mechanism of action (MoA) study for the European based bio-pharma company's CimetrA platform.

Lisovoder says that the fact MGC "totally understands" CimetrA represents a "very important step" in the development process.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/mgc-pharmaceuticals-totally-understands-cimetra-after-moa-study-226216324

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  267.74
+0.00 (0.00%)
AAPL  352.45
+0.00 (0.00%)
AMD  530.14
+0.00 (0.00%)
BAC  48.91
+0.00 (0.00%)
GOOG  279.20
+0.00 (0.00%)
META  616.38
+0.00 (0.00%)
MSFT  508.29
+0.00 (0.00%)
NVDA  150.96
+0.00 (0.00%)
ORCL  113.89
+0.00 (0.00%)
TSLA  383.72
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback